VaLogic Bio offers specialized advisory and compliance services designed to simplify complexity and promote innovation for life science and biotech companies. Our expertise spans consulting, software as a service (SaaS), laboratory services, and certification. We provide strategic guidance, advanced software solutions, precise laboratory support, and certification assistance to help organizations reach new heights, navigate regulatory challenges, and achieve operational excellence.
Valerian Chem Private Ltd
VProteomics, Valerian Chem Pvt. Ltd. to Showcase Advanced Mass Spectrometry Solutions at BIO International Convention 2025 We are excited to announce that VProteomics, Valerian Chem Pvt. Ltd. will be participating in the Innovative India Pavilion at the BIO International Convention 2025, taking place from June 16–19, 2025, at the Boston Convention & Exhibition Center, USA. As a leading provider of high-end mass spectrometry services, VProteomics specializes in proteomics, metabolomics, and clinical diagnostics, catering to academic institutions, medical researchers, and pharmaceutical companies. Our state-of-the-art laboratory in Noida is equipped with the latest mass spectrometry infrastructure, enabling us to deliver precise and reproducible results. Our Core Competencies: Discovery & Targeted Proteomics: Comprehensive protein analysis to elucidate complex biological processes. Advanced Metabolomics: In-depth metabolite profiling to understand metabolic pathways and disease mechanisms. Clinical Mass Spectrometry: Diagnostic services including biomarker detection, enzyme analysis, and toxicology testing, facilitating early disease diagnosis and personalized medicine. Biologics Characterization: Detailed analysis of biologic therapeutics to ensure efficacy and safety. We invite our esteemed clients, collaborators, and partners to visit our booth at the Innovative India Pavilion to explore potential collaborations and learn more about our contributions to the global biotech landscape. Event Details: Event: BIO International Convention 2025 Dates: June 16–19, 2025 Location: Boston Convention & Exhibition Center, Boston, USA Pavilion: Innovative India Pavilion For more information about our services, please visit our website: www.vproteomics.com We look forward to connecting with you in Boston!
UK Health Security Agency
Come and talk to us at the UK Pavilion (765) about how we can help support your research and development requirements with consultancy and assay development from our world-renowned experts, our wide range of specialist services and diagnostics, our high containment facilities and our ability to provide high throughput laboratory analysis capacity. The UK Health Security Agency (UKHSA) is responsible for planning, preventing and responding to external health threats, and providing intellectual, scientific and operational leadership at national and local level, as well as globally. We are an executive agency, sponsored by the Department of Health and Social Care. The Agency operates a network of laboratories across England including centres of excellence at Colindale (London) and Porton (Wiltshire), providing a range of clinical, reference and public health microbiology services including bacteriology, mycology, virology, immunology, and genomics. Leadership in communicable diseases, field epidemiology and rapid investigations is also supported by real-time surveillance and analysis and emergency preparedness and response activities delivered via regional health protection teams. All our laboratories have active research and development interests, including the evaluation of novel vaccines, antimicrobials, and in vitro diagnostics, and all our clinical laboratories can assist with access to clinical samples, including novel and emerging pathogens. Our key services include conducting 4 million regional laboratory tests, analysing 350,000+ reference samples, performing 190,000 genomic sequences annually, handling 40,000 rare pathogen referrals, and processing 500,000 radiation dosimeters yearly. We also offer advanced diagnostic capabilities, world-leading expertise in vaccine evaluation and phage translation/application, and have one of the strongest behavioural science units in UK Government. We employ 3,000 scientists across 30+ disciplines and we maintain strong partnerships with 500+ universities globally. Our intellectual property portfolio includes 165 patents and 64 trademarks. UKHSA’s unique position as a public health organisation combines scientific expertise, laboratory infrastructure, and research capabilities. Our income generated from commercial services strengthens our core health security work, while our collaborative approach with industry and academia drives public health benefits and economic growth. We provide a comprehensive range of specialist health security services and products, addressing challenges in public health protection and disease surveillance. These consist of a range of clinical, reference and public health microbiology services including bacteriology, mycology, virology, immunology, and genomics. Leadership in communicable diseases, field epidemiology and rapid investigations is also supported by real-time surveillance and analysis and emergency preparedness and response activities delivered via regional health protection teams. Our key services include: Radiation personal dosimetry service (processing ~500,000 dosimeters annually) Regional laboratory testing (4 million tests supporting NHS diagnostics and public health outbreaks) Reference services (350,000+ samples for specific pathogen analysis) Genomic sequencing (90,000 next-generation and 100,000 Sanger sequencing samples annually) Rare and Imported Pathogen Laboratory services (40,000 NHS referrals) UKHSA’s competitive advantages include: One of the strongest behavioural science and insights functions in UK Government Employment of 3,000 scientists across 30+ scientific disciplines Extensive intellectual property portfolio (165 patents and 64 registered trademarks) Strong partnerships with academia (500+ universities globally) Advanced diagnostic capabilities and accelerator programme World-leading expertise in phage translation and application High containment facilities for in vivo and in vitro research (BSL 3 and 4) Our value proposition lies in our unique position as a public health organisation combining scientific expertise, extensive laboratory infrastructure, and research capabilities. The income generated from commercial services strengthens our core health security services, while our collaborative approach with industry and academia drives both public health benefits and economic growth.
UK Pavilion
The (UK’s) Department for Business and Trade (DBT) helps businesses export, drives inward and outward investment, negotiates market access and trade deals, and champions free trade. We are an international economic department, responsible for: • supporting and encouraging UK businesses to drive sustainable international growth • ensuring the UK remains a leading destination for international investment • opening markets, moulding the trade environment with new and existing partners which is free and fair • using trade and investment to underpin the government’s agenda for a Global Britain and its ambitions for prosperity, stability and security worldwide. | The UK’s Department for Business and Trade supports international investment into the UK and UK businesses to grow and export. Whether you’re interested in clinical research for innovative products, working with the UK’s world-leading universities, SMEs and spin outs, leveraging our globally-unique datasets or manufacturing complex products at pace and scale, the UK has a strong offer spanning Northern Ireland, Scotland and Wales and would like to work with you. We are joined by 16 inspired, innovative and international UK co-exhibitors eager to connect with you. | The UK’s Department for Business and Trade supports international investment into the UK and UK businesses to grow and export. Whether you’re interested in clinical research for innovative products, working with the UK’s world-leading universities, SMEs and spin outs, leveraging our globally-unique datasets or manufacturing complex products at pace and scale, the UK has a strong offer spanning Northern Ireland, Scotland, Wales and England and would like to work with you. This year, we are joined by 22 UK co-exhibitors eager to connect with you. | The Advanced Propulsion Centre (APC) is the organisation that pulls together exhibitors on the UK Pavilion who have advanced new technology and are looking for partner organisations to sell to or develop this technology with. The APC exists to ensure the UK remains competitive in the research, development and production of low emission technologies. Through our team of specialists we introduce those with good ideas to those who can take them to market, supporting through mentoring and providing access to funding. We are delivering a 10 year programme, launched in 2013. Born out of the collaboration between UK Government and industry, our organisation aims to save 50 million tonnes of CO2, safeguard or create 30,000 jobs in the UK and make £1 billion of match funding available to research and develop low emission propulsion technologies in the UK. | The Advanced Propulsion Centre UK (APC) collaborates with UK government, the automotive industry, and academia to facilitate driving research and investment in zero-emission vehicle manufacturing. Established in 2013 and jointly funded by the Department for Business and Trade (DBT) and the automotive industry, the APC accelerates the technologies that support the transition to zero-emission vehicle manufacturing and towards a net-zero automotive supply chain in the UK. With a proven track record, the APC has facilitated funding for 354 low-carbon and zero-emission projects involving 614 partners. Working with companies of all sizes, this funding since 2013 is estimated to have helped create or safeguard over 59,000 jobs in the UK. The technologies and products are projected to save over 425 million tonnes of CO2. The APC is committed to sustaining and enhancing the UK’s long-term automotive capabilities and investments through knowledge-sharing, collaboration, and innovation.
UI Pharmaceuticals
Contract pharmaceutical services include: Pre-formulation studies Formulation development (including lyophilization cycle development) Clinical supply manufacturing and testing Small scale commercial manufacturing and testing Analytical method development and validation Routine quality control analysis Stability studies Active pharmaceutical ingredient (API) and excipient release testing UI Pharmaceuticals is able to manufacture most dosage forms including sterile solutions and lyophilized powders; tablets; capsules; and non-sterile semisolids and liquids. | UI Pharmaceuticals stands as the longest-running, FDA-registered, university-affiliated pharmaceutical manufacturing facility in the United States. Since 1974, we have been a reliable partner in pharmaceutical product development, manufacturing, and testing, with services covering sterile solutions, lyophilized products, tablets, capsules, and non-sterile formats, including powders, semisolids, and liquids. Our experienced team brings deep industry knowledge and a commitment to the highest standards of quality, ensuring full compliance with cGMP regulations. With a steadfast dedication to client satisfaction, UI Pharmaceuticals supports innovation and excellence in contract pharmaceutical manufacturing and testing.
TubeWriter
TubeWriter labeling systems is a full-feature instrument for printing directly at high-speed on the sides and caps of plastic, glass, and curved surfaces, including tubes, vials, slides, plates and custom labware. It is designed to address automating laboratory printing for assays, protocols and experiments. TubeWriter labeling withstands the harshest of lab conditions; resistant to chemical solvents and surviving long-term storage at -80C and liquid nitrogen. | TubeWriter is an automated labeling systems that prints directly on the surface of any labware eliminating the need for sticky labels. For laboratories that perform medium to high-throughput applications struggling with manual labeling or paper labels, the TubeWriter prints directly on the sides and caps of tubes, vials, plates and unique labware. TubeWriter prints text, images, and barcodes using UV-curable ink that withstands extreme lab conditions, most harsh chemicals and long-term storage at -80C and liquid nitrogen.
TSRL, Inc.
Beyond Testing: Your Strategic Partner for Preclinical Product Development Success The transition from early-stage research to clinical drug development is one of the most challenging phases in the pharmaceutical industry. Many promising drug candidates fail due to insufficient preclinical data, lack of strategic guidance, and funding limitations. At TSRL, Inc., we have built a strong reputation as a preclinical accelerator, helping biotech startups and academic researchers bridge this critical gap as an early-stage funding partner and pharmaceutical product development advisory team. Now, we are expanding our role by offering comprehensive Contract Research Organization (CRO) services, providing the scientific expertise, technical capabilities, and operational support to advance drug candidates toward clinical trials efficiently. Our mission is to provide high-quality preclinical testing that supports regulatory submissions, de-risks development pipelines, and accelerates drug product candidates toward clinical success. 1. Comprehensive Preclinical Testing Services Our AAALAC-accredited research facility in Ann Arbor, MI, is equipped with a vivarium and advanced instrumentation, including HPLC, LC-MS/MS, and spectrophotometry, allowing us to deliver precise, high-quality data to our clients. All studies are conducted in compliance with TSRL SOPs and client-approved protocols and undergo rigorous quality control to ensure accurate and reproducible results. Bioanalysis: Precision Drug Quantification Accurate quantification of drug exposure is critical for determining efficacy, safety, and dosing strategies. TSRL’s bioanalytical services include: HPLC and LC-MS/MS quantification of drugs and metabolites Method development and validation for bioanalytical assays Non-GLP preclinical and clinical sample analysis Our advanced analytical capabilities are customizable to support everything from early-stage research to ICH M10 compliance, providing high-quality data for regulatory filings and clinical trial preparations. Formulation Development: Optimizing Drug Delivery One of the biggest hurdles in drug development is ensuring effective drug delivery. TSRL’s formulation development services focus on enhancing bioavailability, stability, and manufacturability through: Solubility screening and optimization Formulation screening for oral, injectable, and transdermal delivery Preclinical formulation stability testing We develop tailored drug formulations that improve performance and meet target profiles. PK/ADME & Toxicology: Understanding Drug Behavior In vitro ADME (absorption, distribution, metabolism, and excretion) profiling Blood/plasma stability and protein binding assays Microsomal, hepatocyte, and intestinal metabolism studies In vivo PK studies in rodents Mechanistic absorption studies Exploratory toxicology Biodistribution and exposure assessments Early-stage pharmacokinetic and toxicology insights support candidate selection, optimize dosing strategies, and reduce risk prior to clinical development. 2. Strategic Consulting & Regulatory Guidance As TSRL expands its CRO offerings, we continue to provide high-level strategic guidance to ensure drug candidates meet regulatory and clinical development milestones. Our consulting expertise includes: Regulatory Strategy Development – Ensuring preclinical studies align with FDA/EMA guidelines Clinical Planning – Designing data-driven clinical trial strategies Intellectual Property Strategy – Strengthening patents and licensing assets SBIR Grant Strategy – Strengthening the small business funding pipeline TSRL combines scientific rigor with strategic planning to optimize preclinical programs for regulatory approval and market success. 3. Innovative Drug Delivery Technologies Alongside our services, TSRL is advancing next-generation drug delivery technologies to improve therapeutic efficacy and patient outcomes. MicroArray Patch (MAP) Technology Our MAP formulations provide a self-administered drug delivery system that avoids the inconvenience of traditional injections. This hydrogel-based microarray: Provides a drug-releasing reservoir upon skin application Delivers therapeutics directly into systemic circulation Reduces the need for clinic visits and improves patient compliance MAP technology represents a delivery alternative for suboptimal drug products, improving bioavailability, consistency of dosing, and ultimately patient compliance. Prodrug Platform: Enhancing Oral Drug Absorption TSRL’s patent-protected prodrug technology is designed to increase membrane permeability and improve oral bioavailability of challenging compounds. This platform: Optimizes drug absorption in the GI tract Reduces variability in drug exposure Provides a strategy for targeted delivery Minimizes side effects while enhancing therapeutic efficacy This approach has the potential to improve the pharmacological profile of drug candidates, making them more clinically viable and commercially attractive. The TSRL Advantage: A CRO Partner That Goes Beyond Testing TSRL is positioned as a full-service preclinical partner that goes beyond traditional contract research. Unlike many CROs that only offer testing and data generation, we provide end-to-end drug development support, helping clients: Secure non-dilutive funding for early-stage development Generate high-quality preclinical data to support IND applications Optimize drug formulations and delivery methods Develop regulatory strategies to streamline approval processes Whether you are a biotech startup, pharmaceutical company, or academic research team, TSRL’s expanded CRO capabilities provide the scientific expertise, technical resources, and strategic insight needed to accelerate drug candidates from discovery to clinical trials. Ready to streamline your drug development process? Get in touch at BD@tsrlinc.com or visit www.tsrlinc.com.
TrialAssure
TrialAssure® delivers AI Enabled, Human Driven™ solutions for data, document, and image anonymization, medical writing, and clinical trial transparency. With this approach, we help life sciences be efficient, enhance disclosure, and protect patient privacy. Please reach out if you are looking for an AI-enablement partner.
Transpharm Preclinical Solutions
TransPharm is an AAALAC accredited facility, “#001301” and registered with the Office of Laboratory Animal Welfare (OLAW), Assurance #A4747-01. Our only focus is Infectious Disease research, and I believe no one can compete with us regarding passion for this research or match our competitive rate. The company is housed in an interconnected 8,300-sq. ft. complex of buildings including a 3,100-sq. ft. vivarium with an attending 230 sq. ft. surgical suite. The vivarium is split with negative and positive pressured areas equipped with bioBubble® clean rooms. The facility is designed to handle all BSL II Applications. General laboratory work is conducted in a 1,700-sq. ft. wet lab equipped to handle all microbiological procedures and analyses. This work area includes biological containment hoods, sterile workstations, chemical use hoods, and general lab work benches. The entire facility is backed up by a 90,000-watt generator to avoid any catastrophic loss of data. The administrative area includes 1,220 sq. ft. of office space complete with video-link conference room. Our lab is spearheaded by Marci Peek, acting as the Chief Scientific Officer. We have a staff of 6 employees, with most of them being AALAS certified and one being a Board-Certified Veterinary Technician.